APA (7th ed.) Citation

Molnár, P., Demény, M. Á., Várkonyi, B., Polgár, Z., Pór, Á., Kovács, I., . . . Szántó, M. (2025). The clinically applied PARP inhibitor talazoparib ameliorates imiquimod-induced psoriasis in mice without reducing skin inflammation. Frontiers in pharmacology, 16, 1519066. https://doi.org/10.3389/fphar.2025.1519066

Chicago Style (17th ed.) Citation

Molnár, Petra, Máté Ágoston Demény, Beáta Várkonyi, Zsuzsanna Polgár, Ágnes Pór, Ilona Kovács, Andrea Szegedi, Attila Gábor Szöllősi, and Magdolna Szántó. "The Clinically Applied PARP Inhibitor Talazoparib Ameliorates Imiquimod-induced Psoriasis in Mice Without Reducing Skin Inflammation." Frontiers in Pharmacology 16 (2025): 1519066. https://doi.org/10.3389/fphar.2025.1519066.

MLA (9th ed.) Citation

Molnár, Petra, et al. "The Clinically Applied PARP Inhibitor Talazoparib Ameliorates Imiquimod-induced Psoriasis in Mice Without Reducing Skin Inflammation." Frontiers in Pharmacology, vol. 16, 2025, p. 1519066, https://doi.org/10.3389/fphar.2025.1519066.